Evidence map›Paper›PMID 42195135›Full record

ArticleMedicina (Kaunas, Lithuania)2026

Optimal Duration of Adjuvant Platinum-Etoposide in High-Risk Merkel Cell Carcinoma.

Ronen Brenner, Hanna T Frumin Edri, Keren Rouvinov, Noa Shani Shrem, Amichay Meirovitz, Sabri El-Saied, Ilia Berezhnov, Anna Ievko, Sofiia Turaieva, Shlomit Fenig and 5 more

Abstract readMulticenter Study
PubMed Full text at PMC Publisher
In one paragraph

Article in Medicina (Kaunas, Lithuania), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

Ronen BrennerOncology Institute, Edith Wolfson Medical Center, Holon 58220, Israel.
Hanna T Frumin EdriOncology Institute, Edith Wolfson Medical Center, Holon 58220, Israel.
Keren RouvinovThe Legacy Heritage Cancer Center, Dr. Larry Norton Institute, Soroka Medical Center, Beer Sheva 84105, Israel.ORCID 0000-0002-8273-4723
Noa Shani ShremThe Legacy Heritage Cancer Center, Dr. Larry Norton Institute, Soroka Medical Center, Beer Sheva 84105, Israel.ORCID 0000-0002-7708-042X
Amichay MeirovitzThe Legacy Heritage Cancer Center, Dr. Larry Norton Institute, Soroka Medical Center, Beer Sheva 84105, Israel.
Sabri El-SaiedFaculty of Health Sciences, Ben Gurion University of the Negev, Beer Sheva 84105, Israel.
Ilia BerezhnovOncology Institute, Edith Wolfson Medical Center, Holon 58220, Israel.
Anna IevkoOncology Institute, Edith Wolfson Medical Center, Holon 58220, Israel.
Sofiia TuraievaOncology Institute, Edith Wolfson Medical Center, Holon 58220, Israel.
Shlomit FenigInstitute of Oncology, Kaplan Medical Center, Faculty of Medicine, Hebrew University, Jerusalem 91905, Israel.
Nashat Abu YasinThe Legacy Heritage Cancer Center, Dr. Larry Norton Institute, Soroka Medical Center, Beer Sheva 84105, Israel.
Eyal FenigInstitute of Oncology, Davidoff Center, Rabin Medical Center, Beilinson Hospital, Petah Tikva 49414, Israel.
Samer HussanyThe Legacy Heritage Cancer Center, Dr. Larry Norton Institute, Soroka Medical Center, Beer Sheva 84105, Israel.
Alexander YakobsonThe Legacy Heritage Cancer Center, Dr. Larry Norton Institute, Soroka Medical Center, Beer Sheva 84105, Israel.
Walid ShalataThe Legacy Heritage Cancer Center, Dr. Larry Norton Institute, Soroka Medical Center, Beer Sheva 84105, Israel.ORCID 0000-0002-7570-4550

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

Carcinoma, Merkel CellEtoposidePlatinumSkin NeoplasmsAgedAged, 80 and overAntineoplastic Combined Chemotherapy ProtocolsCarboplatinChemotherapy, AdjuvantCisplatinCohort StudiesDisease-Free SurvivalFemaleHumansIsraelMaleCarboplatinCisplatinEtoposidePlatinumadjuvant chemotherapydisease-free survivalMerkel cell carcinomaneuroendocrine carcinomaoverall survivalplatinum–etoposideradiotherapy

Identifiers

PMID42195135
PMCPMC13208469

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.